Femara
In brief
- In the UK and internationally, femara (letrozole) is supplied via pharmacies and hospitals and is strictly prescription‑only (Rx); it is not legally available over the counter and a valid prescription is required.
- Femara is used to treat oestrogen receptor‑positive breast cancer in postmenopausal women (adjuvant, extended adjuvant and advanced/metastatic disease). It is a non‑steroidal aromatase inhibitor that blocks the aromatase enzyme, reducing peripheral oestrogen production and thereby slowing oestrogen‑driven tumour growth.
- The usual dose is 2.5 mg once daily taken orally; adjuvant therapy is commonly given for five years and may be extended according to clinician guidance, and the same daily dose is used for advanced disease.
- Administration is by oral film‑coated tablets (2.5 mg); no injectable, topical or other authorised forms exist.
- Onset: plasma levels peak within about 1 hour after dosing and oestrogen suppression begins within 24–48 hours; measurable clinical effects on disease parameters may take several weeks.
- Duration of action: the drug has a terminal half‑life of approximately 2 days, permitting once‑daily dosing; treatment is continued daily until disease progression or unacceptable toxicity.
- Alcohol warning: there is no specific prohibition on alcohol, but avoid excessive drinking — alcohol can worsen bone health and liver problems, so discuss alcohol use with your prescriber.
- The most common side effect is hot flushes.
- Would you like to try femara without a prescription?
Basic Femara Information
- INN (International Nonproprietary Name): Letrozole
- Brand Names Available In United Kingdom: Femara (2.5 mg tablets, 14 or 30 per pack)
- ATC Code: L02BG04
- Forms & Dosages: Oral film-coated tablets, 2.5 mg; blisters or bottles (7, 10, 14, 28, 30, or 100 tablets).
- Manufacturers In United Kingdom: Novartis Pharma AG (originator) and licensed generics such as Sandoz (UK).
- Registration Status In United Kingdom: not specified
- OTC / Rx Classification: Prescription Only (Rx). Letrozole/Femara is never available over the counter.
Critical Warnings & Restrictions — Safety First (UK Focus)
Are you worried about safety, pregnancy risk or existing health problems while taking femara?
Femara (letrozole) is licensed for post‑menopausal women only and is absolutely contraindicated in pregnancy and lactation because of teratogenic risk.
Femara is prescription only in the United Kingdom and must not be used by pre‑menopausal women.
Patients who could become pregnant must use reliable contraception until treatment is stopped and must contact their GP or oncologist immediately if pregnancy is possible.
High‑Risk Groups
Elderly patients do not routinely require a dose change, but comorbidities should be reviewed carefully.
Patients with pre‑existing osteoporosis or osteopenia need baseline and ongoing bone monitoring.
Severe hepatic or renal impairment, history of ischaemic heart disease, and anyone taking potent CYP450 modulators are higher risk and need specialist review.
- High‑risk signs to watch for: new or severe bone pain or fracture, chest pain or breathlessness, sudden severe fatigue, visual disturbance, symptoms suggesting pregnancy.
- Immediate actions: stop medication and seek urgent review for suspected severe adverse events such as allergic reaction, acute chest pain or neurological change.
Baseline tests checklist before starting letrozole:
- DEXA scan (baseline bone density)
- Lipid profile (total cholesterol and LDL)
- Liver function tests (LFTs)
- Renal function (serum creatinine/estimated GFR)
- Medication review for CYP450 inducers/inhibitors and anticoagulants
| Monitoring Area | When To Check | Action Thresholds / Notes |
|---|---|---|
| Bone Density (DEXA) | Baseline, then 1–2 yearly depending on risk | Start osteoporosis treatment if T‑score ≤‑2.5 or fragility fracture |
| Lipids | Baseline, 3–6 months after starting, then yearly | Treat hypercholesterolaemia according to local guidelines |
| Liver Function | Baseline, if clinical concern or abnormal baseline | Specialist review for severe hepatic impairment |
| Renal Function | Baseline if history of renal disease, then as clinically indicated | Caution if CrCl <10 ml/min; specialist advice required |
Q&A — Can I Drive After Taking It In The UK?
Most patients can drive while taking femara if they feel well enough to do so.
If dizziness, severe fatigue or visual disturbance occurs, stop driving and inform the clinician and insurer immediately.
Report suspected adverse effects via the MHRA Yellow Card scheme.
Usage Basics
INN, Brand Names Available In The UK
The International Nonproprietary Name is letrozole.
Femara is the principal brand seen in regulated markets and in the United Kingdom.
Femara is supplied as 2.5 mg film‑coated tablets, typically in packs of 14 or 30.
Several licensed generics are available, including supplies from Sandoz.
Legal Classification (POM, P, GSL)
Letrozole/Femara is a Prescription Only Medicine in the United Kingdom.
Supply is via NHS prescriptions, private prescriptions or accredited online pharmacies operating with e‑prescriptions.
- INN: Letrozole
- Brand: Femara (2.5 mg tablets)
- Legal Status: Prescription Only Medicine (POM)
- Typical pack sizes: 14 tablets, 30 tablets.
- Sources: NHS community pharmacies, hospital pharmacies, accredited online pharmacies, private clinics.
Dosing Guide
Standard Regimens (NHS Guidelines)
The usual adult dose is 2.5 mg once daily by mouth, with or without food.
Common indications include adjuvant therapy, advanced/metastatic disease and extended adjuvant therapy.
Duration is commonly five years for adjuvant or extended therapy and may be extended up to ten years depending on prior tamoxifen and clinician decision.
Adjustments For Comorbidities
No routine dose change is required for elderly patients or for mild to moderate hepatic or renal impairment.
Patients with severe hepatic impairment or creatinine clearance below 10 ml/min need specialist review before use.
- Take one 2.5 mg tablet once daily at approximately the same time each day.
- Tablets may be taken with food or on an empty stomach.
- Do not crush or chew film‑coated tablets unless pharmacist advises an alternative.
| Indication | Dose | Comments |
|---|---|---|
| Adjuvant Early Breast Cancer | 2.5 mg once daily | Usually 5 years; may be extended with clinician agreement |
| Advanced/Metastatic Disease | 2.5 mg once daily | Continue until progression or unacceptable toxicity |
| Extended Adjuvant | 2.5 mg once daily | May form part of up to 10 years’ total endocrine therapy |
Q&A — What If I Miss A Dose?
Take the missed dose as soon as you remember.
If it is nearly time for the next scheduled dose, skip the missed dose and take the next dose as usual.
Never take a double dose to make up for a missed tablet.
Contact your oncology nurse or GP if several doses are missed or if vomiting occurs soon after taking a tablet.
Interaction Chart
Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)
Letrozole absorption is not meaningfully affected by food and can be taken with or without a meal.
Moderation of alcohol is advised, particularly because alcohol can affect bone health and interact with other oncology treatments.
Common Drug Conflicts (MHRA Yellow Card Data)
Letrozole is metabolised in part by hepatic enzymes and may be affected by potent CYP450 inducers or inhibitors.
Concurrent medications should be reviewed, including herbal remedies and over‑the‑counter preparations.
Monitor anticoagulant therapy and lipid‑lowering strategies where appropriate, since letrozole can influence cholesterol.
| Drug / Class | Interaction Risk | Action |
|---|---|---|
| Potent CYP450 Inducers (e.g. rifampicin) | May reduce letrozole exposure | Avoid if possible; specialist review if co‑prescribing |
| Potent CYP450 Inhibitors | May increase letrozole exposure | Monitor for toxicity; adjust therapy under specialist advice |
| Warfarin / Anticoagulants | Possible interaction affecting INR | Monitor INR closely after starting or stopping letrozole |
| Statins / Lipid‑Lowering Drugs | Indirect interaction via letrozole‑related hypercholesterolaemia | Check lipids and treat per guidelines |
- Drugs to review before starting letrozole: strong CYP450 modulators, long‑term anticoagulants, hormone therapies and interacting herbal products.
- Pharmacist action checklist: perform a full medication review, counsel on interactions, advise monitoring and report suspected interactions to MHRA Yellow Card.
User Reports & Trends
What do patients say about femara on NHS pages and UK forums?
Real‑world reports on NHS.uk, Patient.info and forums often describe hot flushes, joint pain, fatigue and worries about bone density while taking letrozole.
These are patient experience reports and should be discussed with a clinician for tailored management.
- Common patient complaints: hot flushes, arthralgia (joint pain), increased fatigue, nausea and concerns about bone thinning.
Self‑management checklist patients can use:
- Maintain regular weight‑bearing exercise and smoking cessation to protect bone health.
- Ensure adequate calcium and vitamin D intake and follow local DEXA recommendations.
- Use analgesia and physiotherapy for aromatase inhibitor‑related arthralgia after discussing with clinicians.
“I started treatment and noticed joint stiffness after a few weeks; my oncology nurse arranged a DEXA and physiotherapy.”
There is an increasing trend of enquiries about fertility and off‑label ovulation induction using letrozole.
Letrozole is sometimes used off‑label for ovulation induction, but it is not licensed for infertility in many countries and unsupervised use is unsafe.
Report adverse events and experience through the MHRA Yellow Card and consult NHS patient leaflets for formal guidance.
Access & Purchase Options (UK)
High‑Street Chains And Online
Femara and generic letrozole are dispensed through NHS prescriptions at community and hospital pharmacies in the United Kingdom.
Major retail pharmacy chains that commonly dispense oncology prescriptions include Boots, LloydsPharmacy and Superdrug pharmacies that operate NHS services.
Online accredited pharmacies with electronic prescription services can fulfil prescriptions to patients at home.
Private prescriptions are available via GPs, oncologists or private clinics.
In our online pharmacy, femara is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.
| Source | How To Access | Verification Steps |
|---|---|---|
| Community Pharmacy | Present NHS or private prescription | Check GPhC pharmacy registration and NHS prescription documentation |
| Hospital Pharmacy | Supply via hospital oncology clinic | Confirm hospital trust details and clinic letter |
| Accredited Online Pharmacy | Use NHS e‑prescription or upload private prescription | Verify GPhC registration and pharmacy website credentials |
- Documents needed: valid prescription (NHS or private), photographic ID may be requested for private supply.
- Never purchase from unregulated international e‑shops without UK registration or GPhC verification.
Checklist for safe online purchase: verify GPhC number, confirm MHRA‑licensed product or authorised generic, check customer service contact details and returns policy.
Mechanism & Pharmacology
Simplified Explanation
Letrozole is a non‑steroidal aromatase inhibitor that reduces peripheral oestrogen production by blocking the aromatase enzyme.
Lowered oestrogen reduces stimulation of hormone receptor‑positive breast cancer in post‑menopausal women.
Clinical Terms
- Aromatase: enzyme that converts androgens to oestrogens in peripheral tissues.
- Adjuvant Therapy: treatment given after primary surgery to reduce recurrence risk.
- Extended Adjuvant: continued endocrine therapy beyond initial planned years to further reduce relapse.
Pharmacokinetic points:
- Formulation: oral film‑coated tablet only; no injectable or topical forms are authorised.
- Dosage: single 2.5 mg tablet once daily.
- Absorption: oral administration with or without food is acceptable.
Diagram suggestion: a simple flowchart showing aromatase inhibition → reduced oestrogen → decreased tumour growth stimulus.
Indications & Off‑Label Uses
MHRA‑Approved Uses
Letrozole is approved for hormone receptor‑positive breast cancer in post‑menopausal women.
Licensed indications include adjuvant therapy, first‑line advanced/metastatic disease and extended adjuvant therapy at a dose of 2.5 mg once daily.
Off‑Label Practices In NHS And Private Care
Occasional off‑label use includes ovulation induction in specific fertility scenarios but this requires specialist supervision.
Off‑label prescribing must be supported by informed consent and appropriate monitoring.
| Indication | Licensed? | Notes |
|---|---|---|
| Post‑menopausal HR+ Breast Cancer (Adjuvant) | Yes | 2.5 mg once daily; commonly 5 years |
| Advanced/Metastatic HR+ Breast Cancer | Yes | Continue until progression or toxicity |
| Ovulation Induction / Infertility | No (in most countries) | Off‑label; specialist supervision and consent required |
- Ensure documented informed consent for any off‑label use.
- Arrange appropriate monitoring such as fertility clinic follow‑up when used off‑label.
Key Clinical Findings (UK/EU Studies 2022–2025)
Recent cohort analyses and trial updates in UK and EU settings reinforce efficacy for adjuvant use and highlight long‑term safety considerations.
- UK/EU cohort analysis (2022) → finding: prolonged aromatase inhibitor exposure is associated with increased fracture risk → clinical implication: emphasise baseline and periodic DEXA monitoring and bone protective measures.
- Registry updates (2023) → finding: modest increases in total cholesterol in some patients → clinical implication: lipid monitoring and treatment as required.
- Adjuvant trial meta‑analyses (2024) → finding: letrozole provides recurrence‑risk reduction in post‑menopausal women comparable to other aromatase inhibitors → clinical implication: choice between aromatase inhibitors may be based on comorbidity profile and bone risk.
| Trial / Analysis | Population | Outcome |
|---|---|---|
| UK Cohort Analysis 2022 | Post‑menopausal women on aromatase inhibitors | Increased fracture rate with long exposure; DEXA recommended |
| EU Registry Update 2023 | Breast cancer patients on letrozole | Observed lipid rises in a subgroup; monitor lipids |
Citations placeholders: refer to NHS guidance, peer‑reviewed journals and MHRA updates for full study details and local formulary recommendations.
Alternatives Matrix
NHS Prescribing Alternatives (Comparison Table)
| Drug | Mechanism | Typical Dose | Pros | Cons / Bone Impact |
|---|---|---|---|---|
| Anastrozole | Non‑steroidal aromatase inhibitor | 1 mg once daily | Effective alternative to letrozole | Associated with bone density loss similar to other AIs |
| Exemestane | Steroidal aromatase inactivator | 25 mg once daily | Steroidal mechanism; sometimes better tolerated for arthralgia | Also reduces bone density; may have different side‑effect profile |
| Tamoxifen | SERM — oestrogen receptor modulator | 20 mg once daily (varies) | Less adverse effect on bone density in post‑menopausal women | Different risk profile (VTE risk, endometrial effects) |
Pros And Cons Checklist
- Anastrozole: strong efficacy; similar bone risks as letrozole.
- Exemestane: steroidal inactivator; potential tolerability differences for joint symptoms.
- Tamoxifen: bone‑sparing in post‑menopausal women but different vascular and endometrial profile.
Checklist of factors to consider when switching: recurrence risk, bone health, cardiovascular risk, drug interactions, prior endocrine therapy and patient preference.
Common Questions (Patient Consultations)
Will Femara Make Me Infertile?
Letrozole is teratogenic and contraindicated in pregnancy.
Discuss fertility preservation with oncology and fertility specialists before starting endocrine therapy if childbearing is a possibility.
How Will It Affect My Bones And Lipids?
Letrozole increases the risk of bone mineral density loss and may raise cholesterol in some patients.
Baseline DEXA, calcium and vitamin D optimisation, exercise and lipid monitoring are recommended.
Can I Drink Alcohol?
Moderate alcohol consumption is advised while on letrozole.
Alcohol can worsen bone health and interact with overall treatment tolerance.
- Action points for patients: arrange baseline DEXA and blood tests; discuss contraception and fertility; report new bone pain or signs of thromboembolism urgently.
Referral checklist: oncology team for treatment decisions, GP for monitoring and shared care, pharmacist for medication review and interaction checks.
NHS Cost & Access Comparison Table
| Source / Pharmacy | Typical Price Range (Private) | NHS Charge / Exemption Notes |
|---|---|---|
| Community Pharmacy (Private Purchase) | Varies by supplier and pack size; generics lower cost | Standard NHS prescription charge applies in England unless exempt |
| Hospital Oncology Clinic | Usually supplied free via hospital outpatient services | Often provided at no charge to patients under hospital prescribing |
| Accredited Online Pharmacy (Private) | Price varies; check pack size and generic vs originator | NHS e‑prescription service can be used for NHS prescriptions |
| Regional Differences | Prescription Cost Status |
|---|---|
| England | Standard NHS prescription charge per item (verify current NHS fees) |
| Scotland | Prescriptions free |
| Wales | Prescriptions free |
| Northern Ireland | Prescriptions free |
- Eligibility checklist for exemptions: age, certain benefits, war pensions; check current NHS guidance.
- How to use NHS e‑prescription: request e‑prescription from prescriber and nominate a pharmacy.
- Verify online pharmacies by GPhC registration before ordering.
Registration & Regulation
MHRA Approval Process
Letrozole/Femara is a regulated, prescription‑only medicine in the UK market.
Regulatory oversight includes approval of originator and generic products and ongoing pharmacovigilance.
Report adverse events to the MHRA Yellow Card scheme to support safety monitoring.
NHS Prescribing Framework
Prescribing follows local NHS oncology guidelines and hospital formulary decisions.
Shared care agreements may exist between hospital oncology services and primary care for monitoring and repeat prescriptions.
- Regulatory bodies: MHRA, EMA (historical EEA approvals), national health services.
- Pharmacovigilance terms: adverse event reporting, signal detection, safety updates.
Storage & Handling (UK Household/Climate)
UK Household Storage (Cold/Damp Climate)
Store below 30°C and protect from moisture and heat.
Keep tablets in the original blister pack until use and store in a dry cupboard away from bathrooms and windows to avoid damp.
During travel, maintain controlled room temperature below 30°C.
Guidance From NHS And Pharmacists
Keep all medicines out of reach of children and do not flush out‑of‑date tablets down the toilet.
Return unused medication via pharmacy take‑back services for safe disposal.
| Storage Condition | Practical Tip |
|---|---|
| Below 30°C | Store in a bedroom or kitchen cupboard away from heat sources |
| Protect From Moisture | Avoid bathrooms and windowsills |
- Do’s: keep in original packaging, follow expiry dates, record administration times if a carer administers treatment.
- Don’ts: do not share medication, do not flush or bin at home, do not store in high‑humidity areas.
Guidelines For Proper Use (UK Pharmacist Counselling)
UK Pharmacist Counselling Style
Confirm indication and menopausal status before counselling on letrozole.
Highlight teratogenic risk and advise contraception for people who may become pregnant.
Explain common adverse effects such as hot flushes, arthralgia and fatigue and discuss management strategies.
Use teach‑back to confirm understanding and provide a written leaflet and details on Yellow Card reporting.
NHS Patient Safety Advice
Safety net for patients: seek urgent review for signs of severe allergic reaction, acute chest pain, new severe bone pain or sudden neurological symptoms.
Ensure shared care arrangements are documented and patients know how to contact their oncology team.
- Counselling checklist: indication, dose and timing, contraception, bone and lipid monitoring, drug interactions, storage and missed‑dose actions.
- Patient handout template should include contact details, DEXA appointment schedule and Yellow Card reporting instructions.
- Pharmacist script suggestion: confirm patient understands pregnancy risks and monitoring plan; ask patient to repeat back key points.
Delivery Across United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 5-7 days |
| Birmingham | West Midlands | 5-7 days |
| Manchester | Greater Manchester | 5-7 days |
| Glasgow | Scotland | 5-7 days |
| Leeds | West Yorkshire | 5-7 days |
| Edinburgh | Scotland | 5-7 days |
| Bristol | South West | 5-7 days |
| Cardiff | Wales | 5-7 days |
| Belfast | Northern Ireland | 5-7 days |
| Newcastle | North East | 5-9 days |
| Norwich | East of England | 5-9 days |
| Southampton | South East | 5-9 days |
| Coventry | West Midlands | 5-9 days |
| Plymouth | South West | 5-9 days |
Delivery times may vary depending on stock, prescription verification and delivery address.
Always confirm expected delivery at checkout or with pharmacy customer services.
End of article.
